# Chongqing Migesi Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chongqing-migesi-medical-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Chongqing, China
- Total disclosed funding: $1.8M
- Latest round: Series A (May 20, 2025)
- Investors on record: 3

## About

Based in Chongqing, China, and founded in 2022 by Li Jiwei, Chongqing Migesi Medical Technology Co., Ltd operates as a manufacturer of a medical device with active cationic polymer biomaterial technology as its source and focuses on minimally invasive ophthalmology. In May 2025, Chongqing Migesi Medical Technology Co., Ltd raised a series A funding led by new investor Jinkong Fund Management. Other new investors East Lake High Technology Equity Investment Management and Guangzhou Yuefu Fund Management also participated in the round. Chongqing Migesi Medical Technology Co., Ltd operates two businesses: material technology platforms and research and development of minimally invasive ophthalmic devices. The SIBS material system is synthesized by cationic polymerization technology-facilitated under the cooperation of Chengdu Tianfu International Bio-City Biomaterials and Innovation Center. In terms of research and development of minimally invasive devices for ophthalmology, the company's product is minimally invasive surgical devices for glaucoma. In addition to the field of glaucoma, ICL crystals in the field of optometry are also managed by Migos Medical. The company plans to use the angel funding for team building and ophthalmic medical device registration inspection.

## Funding rounds

- Series A, May 20, 2025 — Jinkong Fund Management, East Lake High Technology Equity Investment Management
- Angel, Jul 1, 2022, $1.8M — NLVC

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Angel
- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series A
- East Lake High Technology Equity Investment Management (https://capitalatlas.ai/funds/east-lake-high-technology-equity-investment-management) — Series A